1.
|
15 p, 510.1 KB |
Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy
/
Martín-Aguilar, Lorena (Institut d'Investigació Biomèdica Sant Pau) ;
Lleixà, Cinta (Institut d'Investigació Biomèdica Sant Pau) ;
Pascual-Goñi, Elba (Institut d'Investigació Biomèdica Sant Pau) ;
Caballero-Ávila, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Martinez-Martinez, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Diaz-Manera, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Rojas-Garcia, Ricard (Institut d'Investigació Biomèdica Sant Pau) ;
Cortés-Vicente, Elena (Institut d'Investigació Biomèdica Sant Pau) ;
Turon-Sans, Janina (Institut d'Investigació Biomèdica Sant Pau) ;
De Luna, Noemi (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Suarez-Calvet, Xavier (Institut d'Investigació Biomèdica Sant Pau) ;
Gallardo, Eduard (Institut d'Investigació Biomèdica Sant Pau) ;
Rajabally, Yusuf (Birmingham Women's and Children's Hospital (Regne Unit)) ;
Scotton, Sangeeta (Birmingham Women's and Children's Hospital (Regne Unit)) ;
Jacobs, Bart C. (Erasmus Medical Center) ;
Baars, Adája (Erasmus Medical Center) ;
Cortese, Andrea (Irccs Mondino Foundation) ;
Vegezzi, Elisa (Irccs Mondino Foundation) ;
Höftberger, Romana (Department of Neurology. Medical University of Vienna) ;
Zimprich, Fritz (Department of Neurology. Medical University of Vienna) ;
Roesler, Cornelia (Paracelsus Medical University) ;
Nobile-Orazio, Eduardo (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Liberatore, Giuseppe (Irccs Humanitas Research Hospital. Milan University) ;
Hiew, Fu Liong (Kuala Lumpur General Hospital) ;
Martínez-Piñeiro, Alicia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Carvajal, Alejandra (Hospital Universitario Virgen de las Nieves (Granada)) ;
Piñar-Morales, Raquel (Hospital Universitario San Cecilio (Granada)) ;
Usón-Martín, Mercedes (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Albertí, Olalla (Hospital General San Jorge (Osca)) ;
López Pérez, María Ángeles (Hospital San Pedro de Alcántara) ;
Márquez, Fabian (Hospital Universitari de Girona Doctor Josep Trueta) ;
Pardo-Fernández, Julio (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Muñoz-Delgado, Laura (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Cabrera-Serrano, Macarena (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Ortiz-Castellon, Nicolau (Hospital Universitari de Sant Joan de Reus (Tarragona)) ;
Bartolomé, Manuel (Complejo Asistencial de Ávila) ;
Duman, Özgür (Akdeniz University) ;
Bril, Vera (Toronto General Hospital. University Health Network. University of Toronto) ;
Segura-Chávez, Darwin (Instituto Nacional de Ciencias Neurológicas) ;
Pitarokoili, Kalliopi (St. Josef-Hospital. Ruhr-University Bochum) ;
Steen, Claudia (Sant Joseph Hospital) ;
Illa, Isabel (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Querol, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Background and ObjectivesTo study the clinical and laboratory features of antineurofascin-155 (NF155)-positive autoimmune nodopathy (AN). MethodsPatients with anti-NF155 antibodies detected on routine immunologic testing were included. [...]
2022 - 10.1212/NXI.0000000000001098
Neurology® neuroimmunology & neuroinflammation, Vol. 9 Núm. 1 (february 2022) , p. e1098
|
|
2.
|
12 p, 600.5 KB |
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
/
Carlo-Stella, Carmelo (Humanitas Research Hospital (Itàlia)) ;
Zinzani, Pier Luigi (IRCCS Azienda Ospedaliero-Universitaria di Bologna) ;
Sureda, Anna (Hospital Universitari de Bellvitge) ;
Araújo, Luis (Universitário de Coimbra) ;
Casasnovas, Olivier (CHU Dijon Bourgogne) ;
Carpio Segura, Cecilia del Carmen (Hospital Universitari Vall d'Hebron) ;
Yeh, Su-Peng (China Medical University Hospital) ;
Bouabdallah, Krimo (University Hospital of Bordeaux) ;
Cartron, Guillaume (Centre Hospitalier Universitaire Montpellier) ;
Kim, Won Seog (Samsung Medical Center) ;
Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz) ;
Koh, Youngil (Seoul National University Hospital) ;
Re, Alessandro (ASST Spedali Civili Brescia) ;
Alves, Daniela (Centro Hospitalar Universitário Lisboa Norte) ;
Chamuleau, Martine (Vrije Universiteit Amsterdam) ;
Le Gouill, Steven (Institut Curie) ;
López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Moreira, Ilídia (Portuguese Institute of Oncology of Porto) ;
van der Poel, Marjolein W. M. (Maastricht University Medical Center) ;
Abbadessa, Giovanni (Sanofi) ;
Meng, Robin (Sanofi) ;
Ji, Ran (Sanofi) ;
Lépine, Lucie (Sanofi) ;
Saleem, Rao (Sanofi) ;
Ribrag, Vincent (Institut Gustave Roussy (Villejuif, França)) ;
Universitat Autònoma de Barcelona
Patients with relapsed or refractory lymphoma have limited treatment options, requiring newer regimens. In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti-CD38 antibody) in combination with cemiplimab (Cemi, anti-programmed death-1 [PD-1] receptor antibody; Isa + Cemi) in patients with classic Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma (PTCL). [...]
2022 - 10.1002/hon.3089
Hematological Oncology, Vol. 41 (october 2022) , p. 108-119
|
|
3.
|
12 p, 506.4 KB |
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
/
Stein, Eytan M. (Memorial Sloan Kettering Cancer Center (New York)) ;
DeAngelo, Daniel J. (Dana-Farber Cancer Institute (Boston, Massachusetts)) ;
Chromik, Jörg (Goethe University Frankfurt) ;
Chatterjee, Manik (University Hospital of Würzburg) ;
Bauer, Sebastian (German Consortium of Translational Cancer Research (DKTK)) ;
Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
de Vos, Filip (University Medical Center Utrecht) ;
Steeghs, Neeltje (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Cassier, Philippe A. (Léon Bérard Center) ;
Tai, David (National Cancer Center Singapore) ;
Kiladjian, Jean-Jacques (Université de Paris) ;
Yamamoto, Noboru (National Cancer Center Hospital (Tokyo, Japó)) ;
Mous, Rogier (University Medical Center Utrecht) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Minami, Hironobu (Kobe University Graduate School of Medicine and Hospital (Japó)) ;
Ferretti, Stephane (Novartis Institutes for Biomedical Research) ;
Guerreiro, Nelson (Novartis Institutes for Biomedical Research) ;
Meille, Christophe (Novartis Institutes for Biomedical Research) ;
Radhakrishnan, Rajkumar (Novartis Healthcare Private Limited (Hyderabad, India)) ;
Pereira, Bernard (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Mariconti, Luisa (Novartis Institutes for Biomedical Research) ;
Halilovic, Ensar (Novartis Institutes for BioMedical Research (Cambridge, Massachusetts)) ;
Fabre, Claire (Novartis Institutes for Biomedical Research) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12. [...]
2021 - 10.1158/1078-0432.CCR-21-1295
Clinical Cancer Research, Vol. 28 (december 2021) , p. 870-881
|
|
4.
|
8 p, 132.9 KB |
Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting
/
Muntañola, Ana (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Arguiñano, José M (Hospital Universitario de Navarra) ;
Dávila, Julio (Complejo Asistencial de Ávila) ;
de Villambrosia, Sonia González (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Carpio Segura, Cecilia del Carmen (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Jiménez-Ubieto, Ana (Hospital Universitario 12 de Octubre (Madrid)) ;
Salar, Antonio (Universitat Pompeu Fabra)
Although rituximab is generally well-tolerated, infusion-related reactions (IRRs) are common with the initial dose when administered intravenously according to standard recommendations. To prevent IRRs, premedication and low-speed infusion rates have been recommended. [...]
2022 - 10.1111/cts.13450
Clinical and Translational Science, Vol. 16 (november 2022) , p. 305-312
|
|
5.
|
14 p, 1.3 MB |
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659)
/
Gordon, Leo I. (Northwestern University Feinberg School of Medicine) ;
Karmali, Reem (Northwestern University Feinberg School of Medicine) ;
Kaplan, Jason B. (Northwestern University Feinberg School of Medicine) ;
Popat, Rakesh (University College London) ;
Burris, Howard A. (Sarah Cannon Research Institute/Tennessee Oncology) ;
Ferrari, Silvia (Ospedale Papa Giovanni XXIII) ;
Madan, Sumit (Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA) ;
Patel, Manish R. (Florida Cancer Specialists/Sarah Cannon Research Institute) ;
Gritti, Giuseppe (Ospedale Papa Giovanni XXIII) ;
El-Sharkawi, Dima (Royal Marsden Hospital (Regne Unit)) ;
Chau, F. Ian (Royal Marsden Hospital (Regne Unit)) ;
Radford, John (University of Manchester) ;
de Oteyza, Jaime Pérez (Hospital Universitario HM Sanchinarro (Madrid)) ;
Zinzani, Pier Luigi (Università di Bologna) ;
Iyer, Swaminathan P. (University of Texas MD Anderson Cancer Center) ;
Townsend, William (University College London Hospitals) ;
Miao, Harry (Takeda Development Center Americas) ;
Proscurshim, Igor (Takeda Development Center Americas) ;
Wang, Shining (Takeda Development Center Americas) ;
Katyayan, Shilpi (Labcorp Drug Development (Estats Units d'Amèrica)) ;
Yuan, Ying (Takeda Development Center Americas) ;
Zhu, Jiaxi (Takeda Development Center Americas) ;
Stumpo, Kate (Takeda Development Center Americas) ;
Shou, Yaping (Takeda Development Center Americas) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Universitat Autònoma de Barcelona)
We report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib, presenting data for the overall cohort of lymphoma patients, and the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; including an expanded cohort not included in the initial report). [...]
2023 - 10.18632/oncotarget.28352
Oncotarget, Vol. 14 (january 2023) , p. 57-70
|
|
6.
|
12 p, 927.8 KB |
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
/
Kwon, Mi (Hospital General Universitario Gregorio Marañón) ;
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Reguera-Ortega, Juan Luis (Instituto de Biomedicina de Sevilla) ;
Corral, Lucía López (Instituto de Investigación Biomédica de Salamanca) ;
Morales, Rafael Hernani (Hospital Clínic Universitari (València)) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Guerreiro, Manuel (Hospital Universitari i Politècnic La Fe (València)) ;
Caballero, Ana Carolina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Domínguez, María Luisa Guerra (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Pina, Jose Maria Sanchez (Hospital Universitario 12 de Octubre (Madrid)) ;
Mussetti, Alberto (Institut Català d'Oncologia) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bastos, Mariana (Hospital General Universitario Gregorio Marañón) ;
Catala, Eva (Vall d'Hebron Institut d'Oncologia) ;
Delgado, Javier (Instituto de Biomedicina de Sevilla) ;
Henriquez, Hugo Luzardo (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Sanz, Jaime (Hospital Universitari i Politècnic La Fe (València)) ;
Calbacho, Maria (Hospital Universitario 12 de Octubre (Madrid)) ;
Bailén, Rebeca (Hospital General Universitario Gregorio Marañón) ;
Carpio Segura, Cecilia del Carmen (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Ribera Santasusana, Jose Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sureda, Anna (Institut Català d'Oncologia) ;
Briones Meijide, Javier (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ;
Cebrián, Nuria Martínez (Hospital Clínic i Provincial de Barcelona) ;
Martin, Jose Luis Diez (Universidad Complutense de Madrid) ;
Martín, Alejandro (Instituto de Investigación Biomédica de Salamanca) ;
Barba, Pere (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. [...]
2022 - 10.3324/haematol.2022.280805
Haematologica, Vol. 108 (january 2023) , p. 110-121
|
|
7.
|
|
8.
|
10 p, 2.2 MB |
ZAP-70 Promotes the Infiltration of Malignant B-Lymphocytes into the Bone Marrow by Enhancing Signaling and Migration after CXCR4 Stimulation
/
Calpe, Eva (Hospital Universitari Vall d'Hebron) ;
Purroy i Zuriguel, Noèlia (Hospital Universitari Vall d'Hebron) ;
Carpio Segura, Cecilia del Carmen (Hospital Universitari Vall d'Hebron) ;
Abrisqueta, Pau (Hospital Universitari Vall d'Hebron) ;
Carabia, Júlia (Hospital Universitari Vall d'Hebron) ;
Palacio-García, Carles (Hospital Universitari Vall d'Hebron) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Crespo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
ZAP-70 in chronic lymphocytic leukemia (CLL) is associated with enhanced response to microenvironmental stimuli. We analyzed the functional consequences of ZAP-70 ectopic expression in malignant B-cells in a xenograft mouse model of disseminated B-cell leukemia. [...]
2013 - 10.1371/journal.pone.0081221
PloS one, Vol. 8 (december 2013)
|
|
9.
|
10 p, 3.1 MB |
Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia
/
Carabia, Júlia (Vall d'Hebron Institut d'Oncologia) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Abrisqueta, Pau (Vall d'Hebron Institut d'Oncologia) ;
Jiménez, Isabel (Vall d'Hebron Institut d'Oncologia) ;
Purroy i Zuriguel, Noèlia (Vall d'Hebron Institut d'Oncologia) ;
Calpe, Eva (Vall d'Hebron Institut d'Oncologia) ;
Palacio-García, Carles (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Crespo, Marta (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Chronic lymphocytic leukemia (CLL) cells are highly dependent on microenvironment, being the BCR pathway one key player in this crosstalk. Among proteins participating, ZAP-70 enhances response to microenvironmental stimuli. [...]
2017 - 10.1038/s41598-017-12135-7
Scientific reports, Vol. 7 (september 2017)
|
|
10.
|
15 p, 1.2 MB |
First-in-Human Phase I Study of Iadademstat (ORY-1001) : A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia
/
Salamero, Olga (Vall d'Hebron Institut d'Oncologia) ;
Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer) ;
Willekens, Christophe (Institut Gustave Roussy (Villejuif, França)) ;
Pérez-Simón, José Antonio (Universidad de Sevilla) ;
Pigneux, Arnaud (Centre Hospitalier Universitaire CHU Bordeaux) ;
Récher, Christian (Hospitalier Universitaire de Toulouse) ;
Popat, Rakesh (University College London) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Molinero, César (Parc Científic de Barcelona. Oryzon Genomics) ;
Mascaró, Cristina (Parc Científic de Barcelona. Oryzon Genomics) ;
Vila, Joaquim (Parc Científic de Barcelona. Oryzon Genomics) ;
Arévalo, M. Isabel (Parc Científic de Barcelona. Oryzon Genomics) ;
Maes, Tamara (Parc Científic de Barcelona. Oryzon Genomics) ;
Buesa, Carlos (Parc Científic de Barcelona. Oryzon Genomics) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Somervaille, Tim (The University of Manchester) ;
Universitat Autònoma de Barcelona
This phase I, nonrandomized, open-label, dose-escalation (DE), and extension-cohort (EC) trial included patients with R/R AML and evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antileukemic activity of this orally bioavailable first-in-class lysine-specific demethylase 1 inhibitor. [...]
2020 - 10.1200/JCO.19.03250
Journal of Clinical Oncology, Vol. 38 (october 2020) , p. 4260-4273
|
|